Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4306 AL 4320

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Wu XL, Piña-Crespo J, Zhang YW, Chen XC, Xu HX.

Chin Med J (Engl). 2017 Dec 20;130(24):2978-2990. doi: 10.4103/0366-6999.220313.

Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes

May BH, Feng M, Hyde AJ, Hügel H, Chang SY, Dong L, Guo X, Zhang AL, Lu C, Xue CC.

Int J Geriatr Psychiatry. 2018 Mar;33(3):449-458. doi: 10.1002/gps.4830. Epub 2017 Dec 14.

Nanotherapy for Alzheimer's disease and vascular dementia: Targeting senile endothelium

D'Arrigo JS.

Adv Colloid Interface Sci. 2018 Jan;251:44-54. doi: 10.1016/j.cis.2017.12.002. Epub 2017 Dec 8.

The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial

Li M, Lyu JH, Zhang Y, Gao ML, Li WJ, Ma X.

Medicine (Baltimore). 2017 Dec;96(51):e9381. doi: 10.1097/MD.0000000000009381.

Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series

Devanand DP, Pelton GH, D'Antonio K, Strickler JG, Kreisl WC, Noble J, Marder K, Skomorowsky A, Huey ED.

Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):73-75. doi: 10.1097/WAD.0000000000000161.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

Vitamin E for Alzheimer's dementia and mild cognitive impairment

Farina N, Llewellyn D, Isaac MG, Tabet N.

Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD002854. doi: 10.1002/14651858.CD002854.pub4.

Alzheimer's disease: time to focus on the brain, not just molecules

Husain M.

Brain. 2017 Feb;140(2):251-253. doi: 10.1093/brain/aww353.

Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers

Miki T, Shimada H, Kim JS, Yamamoto Y, Sugino M, Kowa H, Heurling K, Zanette M, Sherwin PF, Senda M.

Ann Nucl Med. 2017 Apr;31(3):260-272. doi: 10.1007/s12149-017-1154-7. Epub 2017 Feb 8.

[Alzheimer's disease and epilepsy]

Haussmann R, Mayer T, Schrempf W, Donix M.

Nervenarzt. 2017 Sep;88(9):1003-1009. doi: 10.1007/s00115-017-0286-2.

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease

Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ.

Alzheimers Res Ther. 2017 Feb 17;9(1):10. doi: 10.1186/s13195-017-0237-y.

Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Fujino T, Yamada T, Asada T, Tsuboi Y, Wakana C, Mawatari S, Kono S.

EBioMedicine. 2017 Mar;17:199-205. doi: 10.1016/j.ebiom.2017.02.012. Epub 2017 Feb 24.

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients

Ketter N, Brashear HR, Bogert J, Di J, Miaux Y, Gass A, Purcell DD, Barkhof F, Arrighi HM.

J Alzheimers Dis. 2017;57(2):557-573. doi: 10.3233/JAD-160216.

An update on the advancements in the treatment of agitation in Alzheimer's disease

Porsteinsson AP, Antonsdottir IM.

Expert Opin Pharmacother. 2017 Apr;18(6):611-620. doi: 10.1080/14656566.2017.1307340. Epub 2017 Mar 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias